Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation

Bibliography

• Stel VS, Kramer A, Zoccali C, The 2007 ERA-EDTA Registry annual report-a precis. NDT Plus 2009;2(6):514-21
   PubMedGoogle Scholar
• U S Renal Data System UADRAoCKDaE-SRDitUS, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2009
   Google Scholar
• Nickeleit V, Hirsch HH, Zeiler M, BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000;15(3):324-32
   PubMed Web of Science ®Google Scholar
• Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010;23(3):253-62
   PubMed Web of Science ®Google Scholar
• Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69(16):2227-43
   PubMed Web of Science ®Google Scholar
• Buhaescu I, Izzedine H, Covic A. Sirolimus – challenging current perspectives. Ther Drug Monit 2006;28(5):577-84
   PubMed Web of Science ®Google Scholar
• Davies NM, Grinyo J, Heading R, Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 2007;22(9):2440-8
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Passerini P. Gastrointestinal complications in renal transplant recipients. Transpl Int 2005;18(6):643-50
   PubMed Web of Science ®Google Scholar
• Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009;4(12):2029-34
   PubMed Web of Science ®Google Scholar
• Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2(9):807-18
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9 (Suppl 3):S1-155
   PubMed Web of Science ®Google Scholar
• Kalble TAA, Budde K, Humke U, Guidelines on renal transplantation. Eur Assoc Urol 2010
   Google Scholar
• Grenda R. Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients. Pediatr Nephrol 2010;25(4):747-52
   PubMed Web of Science ®Google Scholar
• Li L, Chang A, Naesens M, Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant 2009;9(6):1362-72
   PubMed Web of Science ®Google Scholar
• Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004;64(18):2047-73
   PubMed Web of Science ®Google Scholar
• Matas AJ. Steroid elimination-who, when, how? Transplant Proc 2008;40(10 Suppl):S52-6
   PubMedGoogle Scholar
• Keown PA, Stiller CR, Wallace AC. Effect of cyclosporine on the kidney. J Pediatr 1987;111(6 Pt 2):1029-33
   PubMed Web of Science ®Google Scholar
• Webster A, Woodroffe RC, Taylor RS, Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005(4):CD003961
   Google Scholar
• Magnasco A, Rossi A, Catarsi P, Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives. Curr Clin Pharmacol 2008;3(3):166-73
   PubMedGoogle Scholar
• Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: an update. Drugs Today (Barc) 2009;45(7):521-32
   PubMed Web of Science ®Google Scholar
• van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant 2009;9(7):1495-9
   PubMed Web of Science ®Google Scholar
• Atcheson BA, Taylor PJ, Mudge DW, Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol 2005;59(3):271-80
   PubMed Web of Science ®Google Scholar
• Filler G, Buffo I. Safety considerations with mycophenolate sodium. Expert Opin Drug Saf 2007;6(4):445-9
   PubMed Web of Science ®Google Scholar
• Satoh S, Tada H, Murakami M, The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc 2005;37(4):1751-3
   PubMed Web of Science ®Google Scholar
• Halloran P, Mathew T, Tomlanovich S, Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63(1):39-47
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009;87(6):795-802
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Cravedi P, Costantini M, Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007;18(6):1973-85
   PubMed Web of Science ®Google Scholar
• Young DA, Nickerson-Nutter CL. mTOR--beyond transplantation. Curr Opin Pharmacol 2005;5(4):418-23
   PubMed Web of Science ®Google Scholar
• Harris TE, Lawrence JC Jr. TOR signaling. Sci STKE 2003;2003(212):re15
   PubMedGoogle Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18(16):1926-45
   PubMed Web of Science ®Google Scholar
• Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998;10(3):330-6
   PubMed Web of Science ®Google Scholar
• Sanchez-Fructuoso AI. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2008;4(6):807-19
   PubMed Web of Science ®Google Scholar
• Morath C, Arns W, Schwenger V, Sirolimus in renal transplantation. Nephrol Dial Transplant 2007;22(Suppl 8):viii61-5
   PubMedGoogle Scholar
• Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 2010;23(2):133-42
   PubMed Web of Science ®Google Scholar
• Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351(26):2715-29
   PubMed Web of Science ®Google Scholar
• Cooper JE, Wiseman AC. Novel immunosuppressive agents in kidney transplantation. Clin Nephrol 2010;73(5):333-43
   PubMed Web of Science ®Google Scholar
• Gaber A. ISA247: A Phase IIB Multicenter, Open Label, Concentration-Controlled Trial in de novo Renal Transplantation. Am J Transplant abstract #LB06 2008
   Google Scholar
• Quaedackers ME, Mol W, Korevaar SS, Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 2009;88(8):1002-9
   PubMed Web of Science ®Google Scholar
• Busque S, Leventhal J, Brennan DC, Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009;9(8):1936-45
   PubMed Web of Science ®Google Scholar
• Vincenti F, Blancho G, Durrbach A, Five-Year Safety and Efficacy of Belatacept in Renal Transplantation. J Am Soc Nephrol 2010;21(9):1587-96
   PubMed Web of Science ®Google Scholar
• Vincenti F, Charpentier B, Vanrenterghem Y, A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10(3):535-46
   PubMed Web of Science ®Google Scholar
• Durrbach A, Pestana JM, Pearson T, A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010;10(3):547-57
   PubMed Web of Science ®Google Scholar
• Spitaler M, Cantrell DA. Protein kinase C and beyond. Nat Immunol 2004;5(8):785-90
   PubMed Web of Science ®Google Scholar
• Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. Faseb J 1999;13(13):1658-76
   PubMed Web of Science ®Google Scholar
• Li H, Weinstein IB. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res 2006;66(23):11399-408
   PubMed Web of Science ®Google Scholar
• Matsuzaki Y, Takaoka Y, Hitomi T, Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c). Oncogene 2004;23(31):5409-14
   PubMed Web of Science ®Google Scholar
• Blackshear PJ. The MARCKS family of cellular protein kinase C substrates. J Biol Chem 1993;268(3):1501-4
   PubMed Web of Science ®Google Scholar
• Arbuzova A, Schmitz AA, Vergeres G. Cross-talk unfolded: MARCKS proteins. Biochem J 2002;362(Pt 1):1-12
   PubMed Web of Science ®Google Scholar
• Sundaram M, Cook HW, Byers DM. The MARCKS family of phospholipid binding proteins: regulation of phospholipase D and other cellular components. Biochem Cell Biol 2004;82(1):191-200
   PubMed Web of Science ®Google Scholar
• Ogata N, Yamamoto H, Kugiyama K, Involvement of protein kinase C in superoxide anion-induced activation of nuclear factor-kappa B in human endothelial cells. Cardiovasc Res 2000;45(2):513-21
   PubMed Web of Science ®Google Scholar
• Isakov N, Altman A. Protein kinase C(theta) in T cell activation. Annu Rev Immunol 2002;20:761-94
   PubMed Web of Science ®Google Scholar
• Wei JF, Zheng SS. NF-kappa B in allograft rejection. Hepatobiliary Pancreat Dis Int 2003;2(2):180-3
   PubMedGoogle Scholar
• Pfeifhofer C, Kofler K, Gruber T, Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J Exp Med 2003;197(11):1525-35
   PubMed Web of Science ®Google Scholar
• Sun Z, Arendt CW, Ellmeier W, PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000;404(6776):402-7
   PubMed Web of Science ®Google Scholar
• Castrillo A, Pennington DJ, Otto F, Protein kinase Cepsilon is required for macrophage activation and defense against bacterial infection. J Exp Med 2001;194(9):1231-42
   PubMed Web of Science ®Google Scholar
• Aksoy E, Goldman M, Willems F. Protein kinase C epsilon: a new target to control inflammation and immune-mediated disorders. Int J Biochem Cell Biol 2004;36(2):183-8
   PubMed Web of Science ®Google Scholar
• Su TT, Guo B, Kawakami Y, PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002;3(8):780-6
   PubMed Web of Science ®Google Scholar
• Saijo K, Mecklenbrauker I, Santana A, Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med 2002;195(12):1647-52
   PubMed Web of Science ®Google Scholar
• Evenou JP, Wagner J, Zenke G, The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther 2009;330(3):792-801
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Pally C, Beerli C, Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. Transpl Int 2010;23(5):543-52
   PubMed Web of Science ®Google Scholar
• Fang YH, Joo DJ, Lim BJ, AEB-071 versus tacrolimus monotherapy to prevent acute cardiac allograft rejection in the rat: a preliminary report. Transplant Proc 2010;42(3):976-9
   PubMed Web of Science ®Google Scholar
• Manicassamy S. Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis. Curr Opin Investig Drugs 2009;10(11):1225-35
   PubMed Web of Science ®Google Scholar
• Wagner E, Zenke, The First in-class Oral Protein Kinase C Inhibitor NVP-AEB071 Prolongs Renal Allograft Survival in Non-Human Primates and Suppresses Lymphocyte Proliferation at Safe Exposures in Human Proof-Of-Concept Studies. Supplement to Transplantation 2006;82: abstract 57
   Google Scholar
• Wagner J, von Matt P, Sedrani R, Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. J Med Chem 2009;52(20):6193-6
   PubMed Web of Science ®Google Scholar
• Matz M, Weber U, Mashreghi MF, Effects of the new immunosuppressive agent AEB071 on human immune cells. Nephrol Dial Transplant 2010;25(7):2159-67
   PubMed Web of Science ®Google Scholar
• Burkhart C. Blood PK. PD Measurements of the Novel Protein kinase C Inhibitor NVP-AEB071 (AEB) Correlate with Heart Allograft Survival Times in Rat. AM J Transplant 2007;(Suppl 2): abstract #1090
   Google Scholar
• Bigaud M. Pharmacodynamics (PD) of T-cell inhibition by the new protein kinase C (PKC) inhibitor, NVP-AEB071 (AEB), in non-human primates (NHP). AM J Transplant 2006;6(Suppl 2): abstract #1896
   PubMed Web of Science ®Google Scholar
• Skvara H, Dawid M, Kleyn E, The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008;118(9):3151-9
   PubMed Web of Science ®Google Scholar
• Slade A. NVP-AEB071:Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single Doses from 10 to 1100 mg. Am J Transplant 2007;7(Suppl 2): abtract #145
   Google Scholar
• Kovarik JM, Stitah S, Slade A, Sotrastaurin and cyclosporine drug interaction study in healthy subjects. Biopharm Drug Dispos 2010;31(5-6):331-9
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Stitah S, Slade A, Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses. J Clin Pharmacol 2010;50(11):1260-6
   Google Scholar
• Budde K, Sommerer C, Becker T, Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am J Transplant 2010;10(3):571-81
   PubMed Web of Science ®Google Scholar
• Budde K. Novel T-Cell assay to assess effects of sotrastaurin, a protein kinase C-inhibitor, in combination with tacrolimus. ESOT 2009; abstract #0256
   Google Scholar
• Kovarik JM. Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. Transplantation 2010; In press
   Google Scholar
• Kovarik JM, Slade A. Overview of sotrastaurin clinical pharmacokinetics. Ther Drug Monit 2010;32(5):540-3
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Bartlett M, Rordorf C, Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. Int J Clin Pharmacol Ther 2010;48(2):103-8
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29(6):687-710
   PubMed Web of Science ®Google Scholar
• Christians U, Strom T, Zhang YL, Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006;28(1):39-44
   PubMed Web of Science ®Google Scholar
• Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging 2009;26(9):715-37
   PubMed Web of Science ®Google Scholar
• Kuypers DR. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant 2008;13(3):11-18
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Huang HL, Slade A, The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. Br J Clin Pharmacol 2009;68(3):381-5
   PubMed Web of Science ®Google Scholar
• Kovarik JM. Comparative pharmacokinetics of a sotrastaurin-everolimus versus a cyclosporine-everolimus regimen in de novo kidney transplant recipients: 934. Supplement to Transplantation 2010;90: abstract O37
   Google Scholar
• Slade A. NVP-AEB071 pharmacokinetics: combination with mycophenolate mofetil is safe and does not result in an interaction. Supplement to Transplantation 2006;82(Suppl 2): abstract 2436
   Google Scholar
• Slade A. AEB071 Pharmacokinetics:effect of hepatic impairment and consequent changes in serum protein concentrations. Am J Transplant 2009;9(Suppl 2): abstract #752
   Google Scholar
• Kovarik JM. Pharmacokinetics of AEB071, a protein kinase C inhibitor, in de novo liver transplant recipients. Am J Transplant 2009;9(Suppl 2): abstract #1219
   Google Scholar
• Friman A, Arn W, Banas B, AEB071, a novel protein kinase C-inhibitor:evaluation of an AEB071 plus mycophenolate regimen in renal transplant recipients. Am J Transplant 2009(Suppl 2): abstract #458
   Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509
   PubMed Web of Science ®Google Scholar